usefulness of Monteleukast in acute asthma in childre
Not Applicable
- Conditions
- Health Condition 1: null- Childhood Asthma
- Registration Number
- CTRI/2015/01/005423
- Lead Sponsor
- Fluid research FundChristian Medical college
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 104
Inclusion Criteria
Children aged 5-15 completed years with a diagnosis of asthma presenting with mild to moderate acute exacerbation (modified pulmonary index score 5-11)
Exclusion Criteria
1.Severe exacerbations with a modified pulmonary index score >12.
2.Children who have been already started on oral steroids for present exacerbation
3.Children on treatment with daily monteleukast in the last month
4.Children who cannot remain in hospital for atleast 4 hours from the onset of treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modified pulmonary index score 4 hours after study drug.Reduction in score will be compared with placebo armTimepoint: Modified Pulmonary Index Score(MPIS)measured at 0 hour and 4 hours.
- Secondary Outcome Measures
Name Time Method Improvement in peak expiratory flow rateTimepoint: from baseline to 4 hours and 36 -48 hours;need for steroid useTimepoint: 4 hours and 36-49 hours;subjective improvement of symptoms using visual analog scaleTimepoint: from baseline to 4 hours and 36 -48